Organization of a United States County System for Comprehensive Acute Stroke Care

Background and Purpose— Organized systems of care have the potential to improve acute stroke care delivery. The current report describes the experience of implementing a county-wide system of spoke-and-hub stroke neurology receiving centers (SNRC) that incorporated several comprehensive stroke center recommendations. Methods— Observational study of patients with suspected stroke of <5 hours duration transported by emergency medical system personnel to an SNRC during the first year of this system. Results— A total of 1360 patients with suspected stroke were evaluated at 9 hub SNRC, of which 553 (40.7%) had a discharge diagnosis of ischemic stroke. Of these 553, intravenous tissue-type plasminogen activator was administered to 110 patients (19.9% of ischemic strokes). Care at the 6 neurointerventional-ready SNRC was a major focus in which 25.1% (99/395) of the patients with ischemic stroke received acute intravenous or intra-arterial reperfusion therapy, and in which provision of such therapies was less common with milder stroke, older age, and Hispanic origin. The door-to-needle time for intravenous tissue-type plasminogen activator met the <60-minute target in only 25% of patients and was 37% longer (P=0.0001) when SNRC were neurointerventional-ready. Conclusions— A stroke system that incorporates features of comprehensive stroke centers can be effectively implemented with substantial rates of acute reperfusion therapy administration. Experiences potentially useful to broader implementation of comprehensive stroke centers are considered.

[1]  R E Latchaw,et al.  Recommendations for the establishment of primary stroke centers , 2000 .

[2]  M. Hadley,et al.  Recommendations for Comprehensive Stroke Centers: A Consensus Statement From the Brain Attack Coalition , 2005, Stroke.

[3]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.

[4]  Dawn Kleindorfer,et al.  Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years , 2011, Stroke.

[5]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[6]  M. C. Gibbons,et al.  Racial Disparities in Tissue Plasminogen Activator Treatment Rate for Stroke: A Population-Based Study , 2011, Stroke.

[7]  L. Castilla-Guerra,et al.  Secondary stroke prevention in the elderly: new evidence in hypertension and hyperlipidemia. , 2009, European journal of internal medicine.

[8]  Adrian F Hernandez,et al.  Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.

[9]  C. Wolfe,et al.  Older stroke patients in Europe: stroke care and determinants of outcome. , 2004, Age and ageing.

[10]  OpeoluAdeoye,et al.  Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States , 2011 .

[11]  D. Bravata,et al.  Metrics for Measuring Quality of Care in Comprehensive Stroke Centers: Detailed Follow-Up to Brain Attack Coalition Comprehensive Stroke Center Recommendations: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[12]  Association Between Stroke Center Hospitalization for Acute Ischemic Stroke and Mortality , 2012 .

[13]  S. Cramer,et al.  Stroke care delivery before vs after JCAHO stroke center certification , 2006, Neurology.